Evidence map›Paper›PMID 40943350›Full record

ArticleInternational journal of molecular sciences2025

Identification of Inflammation Markers as Novel Potential Predictors of the HIV-DNA Reservoir Size.

Erick De La Torre Tarazona, Elisa Moraga, María Fons-Contreras, Raúl Vaquer, Sonsoles Sánchez-Palomino, Germán Vallejo-Palma, Sergio Calderón-Vicente, Sònia Vicens-Artés, Teresa Aldamiz-Echevarria, Marianela Ciudad Sañudo and 8 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Erick De La Torre TarazonaInfectious Diseases Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28034 Madrid, Spain.ORCID 0000-0003-0325-3735
Elisa MoragaHIV Unit, Infectious Diseases Service, Hospital Clinic, IDIBAPS, AIDS and HIV Research Group, University of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0001-5913-364X
María Fons-ContrerasInfectious Diseases Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28034 Madrid, Spain.
Raúl VaquerInfectious Diseases Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28034 Madrid, Spain.ORCID 0009-0007-3523-6071
Sonsoles Sánchez-PalominoCentro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0002-9142-812X
Germán Vallejo-PalmaGeneral Pediatrics and Infectious and Tropical Diseases Department, Hospital La Paz, 28046 Madrid, Spain.ORCID 0009-0001-0770-0355
Sergio Calderón-VicenteInfectious Diseases Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28034 Madrid, Spain.ORCID 0000-0003-1328-2847
Sònia Vicens-ArtésHIV Unit, Infectious Diseases Service, Hospital Clinic, IDIBAPS, AIDS and HIV Research Group, University of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0002-3839-0417
Teresa Aldamiz-EchevarriaCentro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0002-4374-6940
Marianela Ciudad SañudoHospital Universitario de La Princesa, 28006 Madrid, Spain.
Cristina MorenoCentro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Inés Armenteros-YeguasCentro Sanitario Sandoval, Hospital Universitario Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, 28010 Madrid, Spain.
Juan TiraboschiHIV Unit and Infectious Diseases Service, Hospital Universitari de Bellvitge, 08907 Barcelona, Spain.
Sergio Reus BañulsInfectious Diseases Unit, Hospital General Universitario Dr. Balmis de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante, 03010 Alicante, Spain.ORCID 0000-0002-3320-9754
José AlcamíHIV Unit, Infectious Diseases Service, Hospital Clinic, IDIBAPS, AIDS and HIV Research Group, University of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0003-0023-7377
Sergio Serrano-VillarInfectious Diseases Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28034 Madrid, Spain.ORCID 0000-0002-5447-3554
Santiago MorenoInfectious Diseases Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28034 Madrid, Spain.ORCID 0000-0002-2843-1094
On Behalf Of The CoRIS Cohort

Funding

Instituto de Salud Carlos III PI20/00945Instituto de Salud Carlos III PI23/01896
6 · The paper itself

Abstract

The dynamics of the HIV reservoir during antiretroviral therapy (ART) exhibit variability, with a pronounced decline during the initial years of treatment. However, the identification of biomarkers and host factors associated with the decay of the different forms of HIV proviruses remains to be fully elucidated. We conducted a longitudinal study on people with HIV provided by the Spanish National HIV cohort. We assessed the HIV-DNA levels by Intact Proviral DNA Assay, and inflammatory markers using the Proximity Extension Assay, before and after ART initiation. A multivariate linear regression model was employed to identify potential predictive markers. Our results highlight the identification of novel inflammatory markers, such as ADA, DNER, CDCP1, SCF, among others, that varied significantly over ART initiation. In addition, we observed several markers associated with intact HIV-DNA before ART initiation (CD8A, CX3CL1, and ST1A1) or during undetectable viral load post-ART (IL-10). Moreover, up to five markers were able to predict the intact HIV reservoir decay over ART. The strongest predictor was Stem Cell Factor (SCF), where higher baseline levels of this marker were associated with a greater decline in the intact HIV reservoir. In conclusion, we have identified inflammatory markers associated with the size and dynamics of the HIV-DNA reservoir. These findings provide new insights that could contribute to the development of multi-targeted intervention strategies aimed at modulating or monitoring the HIV reservoir size.

Indexed as

DNA, ViralHIVHIV InfectionsInflammationViral LoadAdultAnti-Retroviral AgentsBiomarkersFemaleHumansLongitudinal StudiesMaleStem Cell FactorAnti-Retroviral AgentsBiomarkersDNA, ViralStem Cell FactorHIV reservoirinflammatory markersintact provirusesstem cell factor

Identifiers

PMID40943350
PMCPMC12428898

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.